Enanta Pharmaceuticals Inc
ENTA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$12.00
KIRA · Stoqly’s AI analyst, in plain words
- Enanta Pharmaceuticals Inc had $65.3M of revenue in fiscal 2025, down 3.4% on the year before. Over five years, revenue changed −11.8% a year on average.
- Its operating margin was −130.7%, up 49.3 pts: of every 100 in sales, about −131 is left after running the business.
- Enanta Pharmaceuticals Inc lost $81.9M in fiscal 2025.
- Free cash flow was −$32.2M in fiscal 2025, −49.2% of revenue.
Market cap
$349M
P/E
—
Revenue
$65.3M
Net income
−$81.9M
Free cash flow
−$32.2M
Operating margin
−130.7%
Enanta Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
−3.4%
No. Sales fell 3.4% last year.
Does it make a profit?
−125.4%
No. It lost money last year.
Does profit turn into cash?
−49.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Enanta Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Nov 19, 2025
- Legal name
- ENANTA PHARMACEUTICALS INC
- CIK
- 0001177648
Enanta Pharmaceuticals Inc · ENTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Revenue growth | −20.7% | −11.2% | −8.1% | −14.6% | −3.4% |
| Operating margin | −112.9% | −143.7% | −173.2% | −179.9% | −130.7% |
| Net income | −$79.0M | −$122M | −$134M | −$116M | −$81.9M |
| Net margin | −81.4% | −141.3% | −169.0% | −171.6% | −125.4% |
| Diluted EPS | −$3.92 | −$5.91 | −$6.38 | −$5.48 | −$3.84 |
| Cash | |||||
| Cash from operations | −$70.0M | −$84.8M | −$103M | −$78.8M | −$19.3M |
| Capital expenditure | $0.8M | $2.1M | $9.1M | $17.9M | $12.9M |
| Free cash flow | −$70.7M | −$86.9M | −$112M | −$96.7M | −$32.2M |
| FCF margin | −72.9% | −100.9% | −141.7% | −143.0% | −49.2% |
| Share count change | 1.5% | 2.0% | 1.9% | 1.0% | 0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $244M | $249M | $370M | $248M | $189M |
| Shareholders' equity | $399M | $321M | $217M | $129M | $64.7M |
| Current ratio | 8.8x | 10.5x | 6.7x | 5.2x | 4.2x |
| Interest coverage | — | — | −26.7x | −11.1x | −11.1x |
| Returns and quality | |||||
| Return on equity | −18.5% | −33.8% | −49.7% | −67.2% | −84.6% |
| Return on tangible equity | −19.8% | −37.9% | −61.7% | −90.1% | −126.5% |
| Piotroski F-score | 1 | 3 | 2 | 2 | 3 |
| Altman Z'' | 13.6 | 8.3 | 2.6 | −0.2 | −2.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Enanta Pharmaceuticals Inc · ENTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.00 a share, the company is worth $349M.
Source: SEC EDGAR XBRL filings (CIK 0001177648). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.